|
A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors Clinical research trials and A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors. A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors clinical trial. Subjects typically recieve the finest healthcare available for their A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors  A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors
A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors
For Condition: Neoplasms
Status: Completed
Sponsor(s): Kosan Biosciences ,
Synopsis: Epothilone D represents one of a class of cytotoxic macrolides capable of causing mitotic arrest by stabilizing tubulin polymerization. Since microtubules are essential for mitosis, motility, secretion and proliferation, the observed antitumor effects of epothilones have been attributed to their ability to initiate cell death by inhibiting such processes. Epothilone D has demonstrated in vitro cytotoxic activity in a panel of human cell lines, equipotent to that of paclitaxel. In vivo, Epothilone D has also shown significant antitumor activity in a range of xenograft models, including paclitaxel-resistant xenografts. Epothilone D is more potent than paclitaxel in cell lines that demonstrate multiple drug resistant activity overexpressing p-glycoprotein.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: 1.Diagnosis of histologically documented, advanced stage, primary or metastatic adult solid tumors that are refractory to standard therapy or for which no curative standard therapy exists. This includes but is not limited to cancers of the breast, ovary, head and neck, esophagus, lung, gastrointestinal tract, and sarcomas. 2.Evidence of radiographically measurable or evaluable disease. Exclusion Criteria: 1.Pre-existing peripheral neuropathy of CTC Grade > 2 due to any cause. 2.Documented hypersensitivity reaction (CTC Grade > 2) to prior paclitaxel or other therapy containing Cremophor.
Total Enrollment: 45
Location and Contact Information:
Overall Study Official:
LeeRosen, Principal Investigator, UCLA Division of Hematology-Oncology
UCLA Medical Center
Los Angeles, California, 90095-7059
United States
Additional Information:
Study ID Numbers: KOS-101;
Study Start Date: October 2001
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00030173
Other Neoplasms Studies:
1. Phase 1 Study OF CDC-501 in Patients with Solid Tumors
2. Intrathecal Gemcitibine to Treat Neoplastic Meningitis
3. Liposome Encapsulated SN38 (LE-SN38) in Patients with Advanced Cancer
4. STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
5. Study to Determine Maximum Tolerated Dose of LErafAON Combined with Radiotherapy in Patients with Advanced Malignancies
Related Studies:
Other Neoplasms Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
A Trial to Evaluate Epothilone D in Patients with Advanced Solid Tumors
|
|
|
|
|
|
|
|
